Show simple item record

dc.contributor.authorAu, L
dc.contributor.authorFendler, A
dc.contributor.authorShepherd, STC
dc.contributor.authorRzeniewicz, K
dc.contributor.authorCerrone, M
dc.contributor.authorByrne, F
dc.contributor.authorCarlyle, E
dc.contributor.authorEdmonds, K
dc.contributor.authorDel Rosario, L
dc.contributor.authorShon, J
dc.contributor.authorHaynes, WA
dc.contributor.authorWard, B
dc.contributor.authorShum, B
dc.contributor.authorGordon, W
dc.contributor.authorGerard, CL
dc.contributor.authorXie, W
dc.contributor.authorJoharatnam-Hogan, N
dc.contributor.authorYoung, K
dc.contributor.authorPickering, L
dc.contributor.authorFurness, AJS
dc.contributor.authorLarkin, J
dc.contributor.authorHarvey, R
dc.contributor.authorKassiotis, G
dc.contributor.authorGandhi, S
dc.contributor.authorCrick COVID-19 Consortium
dc.contributor.authorSwanton, C
dc.contributor.authorFribbens, C
dc.contributor.authorWilkinson, KA
dc.contributor.authorWilkinson, RJ
dc.contributor.authorLau, DK
dc.contributor.authorBanerjee, S
dc.contributor.authorStarling, N
dc.contributor.authorChau, I
dc.contributor.authorCAPTURE Consortium
dc.contributor.authorTurajlic, S
dc.date.accessioned2021-08-12T09:07:22Z
dc.date.available2021-08-12T09:07:22Z
dc.date.issued2021-05-26
dc.identifier.citationNature medicine, 2021
dc.identifier.issn1078-8956
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4743
dc.identifier.eissn1546-170X
dc.identifier.eissn1546-170Xen_US
dc.identifier.doi10.1038/s41591-021-01387-6
dc.identifier.doi10.1038/s41591-021-01387-6en_US
dc.description.abstractPatients with cancer are currently prioritized in coronavirus disease 2019 (COVID-19) vaccination programs globally, which includes administration of mRNA vaccines. Cytokine release syndrome (CRS) has not been reported with mRNA vaccines and is an extremely rare immune-related adverse event of immune checkpoint inhibitors. We present a case of CRS that occurred 5 d after vaccination with BTN162b2 (tozinameran)-the Pfizer-BioNTech mRNA COVID-19 vaccine-in a patient with colorectal cancer on long-standing anti-PD-1 monotherapy. The CRS was evidenced by raised inflammatory markers, thrombocytopenia, elevated cytokine levels (IFN-γ/IL-2R/IL-18/IL-16/IL-10) and steroid responsiveness. The close temporal association of vaccination and diagnosis of CRS in this case suggests that CRS was a vaccine-related adverse event; with anti-PD1 blockade as a potential contributor. Overall, further prospective pharmacovigillence data are needed in patients with cancer, but the benefit-risk profile remains strongly in favor of COVID-19 vaccination in this population.
dc.formatPrint-Electronic
dc.languageeng
dc.language.isoeng
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectCrick COVID-19 Consortium
dc.subjectCAPTURE Consortium
dc.titleCytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2.
dc.typeJournal Article
dcterms.dateAccepted2021-05-07
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1038/s41591-021-01387-6
rioxxterms.licenseref.startdate2021-05-26
rioxxterms.licenseref.startdate2021-05-26en_US
dc.relation.isPartOfNature medicine
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/ImmNet
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/ImmNet
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.embargo.termsNot known
dc.contributor.icrauthorBanerjee, Susanaen
dc.contributor.icrauthorChau, Ianen
dc.contributor.icrauthorTurajlic, Samraen
dc.contributor.icrauthorFurness, Andrewen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/